The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.

Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate ...

Johnson & Johnson beats profit estimates, raises sales forecast and plans orthopedics spin-off to focus on higher-growth ...

Beyond the banks, we hear from Johnson & Johnson, which should have the strongest numbers of any pharmaceutical company.

Johnson & Johnson reported third-quarter sales of $24 billion, beating the FactSet consensus estimate of $23.8 billion.

Guidance was raised again, with operational sales growth midpoint moving to 5.1% (previous: 4.8%) and reported sales growth midpoint at 5.7% (previous: 5.4%), reflecting increased confidence in both ...

Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device ...

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion ...

Johnson & Johnson (NYSE: JNJ) announced today that it intends to separate its DePuy Synthes Orthopaedics business.

Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelheim offered up to $991 million ...

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks ...

Johnson & Johnson said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy ...